Oded Kraft: "GrayMatters Health (GMH) was founded with the goal of developing a digital self-neuromodulation therapy for mental diseases that would allow patients to reclaim control over their emotion management. Prism is a non-invasive adjunct therapy developed by GMH that uses unique neuroscience-based and brain-mechanism-specific biomarkers. Prism for PTSD, our first product candidate, is being tested at five clinical sites across the United States and Israel to determine its efficacy and safety as an addition to current PTSD treatments. Professor Talma Hendler and her team at Tel Aviv Sourasky Medical Center and Tel Aviv University created the groundbreaking device.
We were delighted to find that GMH had been admitted into the DE:HUB CUBEX ecosystem. This was a critical step last year in developing our operations in Germany and Europe. Since then, we've witnessed how the CUBEX team, the LSA team, and the 5-ht teams have all worked together and responded to our requests in a professional and effective manner. Due to COVID, we only met the CUBEX team for a highly productive series of face-to-face discussions earlier this month (May 2022). This relationship is taking off in parallel with other firm activity in Europe and with premier medical centers in Germany, resulting in a strong momentum for bringing novel and effective medical therapy for mental diseases to the market."